drugset / Trial / NCT05757700
Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma
NaSequentialOpen-labelTreatment
Summary
The purpose of this research is to evaluate if study therapy, 19(T2)28z1xx TRAC-chimeric antigen receptor (CAR) T cells, may be an effective treatment for people with relapsed/refractory B-cell lymphoma. Researchers will also evaluate if this study therapy is safe, and to look for the highest dose that causes few or mild side effects in participants.
Timeline
- Start
- 2023-02-23
- Primary completion
- 2027-02-23
- Completion
- 2027-02-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 19(T2)28z1xx TRAC T cell | Cell therapy | 3e+06 cells | — |
| Subject | 19(T2)28z1xx TRAC T cell | Cell therapy | 1e+07 cells | — |
| Subject | 19(T2)28z1xx TRAC T cell | Cell therapy | 3e+07 cells | — |
| Subject | 19(T2)28z1xx TRAC T cell | Cell therapy | 1e+08 cells | — |